Goldman Sachs
MLTX icon

Goldman Sachs’s MoonLake Immunotherapeutics MLTX Stock Holding History

Goldman Sachs’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Sell
129,434
-1,000,799
-89% -$18.1M ﹤0.01% 4489
2026
Q1 		$21.1M Buy
1,130,233
+859,568
+318% +$14.2M ﹤0.01% 2386
2025
Q4 		$3.57M Sell
270,665
-92,206
-25% -$1.09M ﹤0.01% 4069
2025
Q3 		$2.6M Sell
362,871
-912,698
-72% -$47.6M ﹤0.01% 4254
2025
Q2 		$60.2M Sell
1,275,569
-17,039
-1% -$694K 0.01% 1204
2025
Q1 		$50.5M Sell
1,292,608
-382,056
-23% -$16.5M 0.01% 1219
2024
Q4 		$90.7M Buy
1,674,664
+178,833
+12% +$9.13M 0.01% 861
2024
Q3 		$75.4M Buy
1,495,831
+244,084
+19% +$11.4M 0.01% 944
2024
Q2 		$55M Buy
1,251,747
+1,093,587
+691% +$46.3M 0.01% 1100
2024
Q1 		$7.94M Buy
158,160
+7,026
+5% +$381K ﹤0.01% 2693
2023
Q4 		$9.13M Buy
151,134
+54,447
+56% +$2.81M ﹤0.01% 2617
2023
Q3 		$5.51M Buy
96,687
+7,186
+8% +$397K ﹤0.01% 2898
2023
Q2 		$4.56M Buy
+89,501
New +$2.41M ﹤0.01% 3180
2023
Q1 		– Sell
-10,110
Closed -$106K – 6120
2022
Q4 		$106K Sell
10,110
-100
-1% -$889 ﹤0.01% 5469
2022
Q3 		$79K Sell
10,210
-1,575
-13% -$11.1K ﹤0.01% 5734
2022
Q2 		$62K Buy
+11,785
New +$74.1K ﹤0.01% 5981

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's MLTX Position: Q2 2026 in Review

Goldman Sachs reduced its MoonLake Immunotherapeutics (MLTX) stake by 89% in Q2 2026, selling an estimated $18.1M and leaving 129,434 shares worth $2.52M. The position accounts for ﹤0.01% of the portfolio, ranked #4489.

Goldman Sachs first reported a position in MLTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $90.7M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Goldman Sachs held 129,434 shares of MoonLake Immunotherapeutics worth $2.52M as of Q2 2026.
  • Goldman Sachs sold 1,000,799 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $18.1M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4489 holding.
  • Goldman Sachs first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 16 quarters since.
  • Goldman Sachs's MoonLake Immunotherapeutics position peaked at $90.7M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.